MEDIPHARM LABS SUBSIDIARY SIGNS $35M DEAL

(LABS.V) Feb. 12, 2019 – MediPharm Labs Corp. has announced that its wholly-owned subsidiary, MediPharm Labs Inc., has entered into a significant sales agreement with a leading licensed producer to supply approximately $35 million of private-label purified cannabis oil concentrates.

Under the terms of the agreement, the licensed producer will immediately purchase upfront $7.66 million of cannabis oil concentrate from MediPharm Labs’ inventory in February. In addition, the licensed producer will purchase a minimum of $27 million of cannabis oil concentrate over a 12-month period commencing in March, with an option to purchase an additional $13.5 million over the same period, bringing the total potential aggregate value of the agreement to over $48 million to February 2020.

MediPharm Labs’ private-label program is a high-margin business for the company, whereby it opportunistically procures dry cannabis flower and trim from its 13 product supply partners to produce proprietary cannabis oil concentrate products for resale globally on a private-label basis. This is MediPharm Labs’ fourth private-label sales agreement to date. In total, these four agreements have aggregate potential value of over $85 million in the 15-month period that commenced December 2018.

“As the cannabis industry continues to rapidly grow and evolve, MediPharm Labs has quickly established itself as a dominant player and leading provider of private label cannabis oil concentrates to other licensed producers and branded product manufacturers,” said CEO Pat McCutcheon. “We have also demonstrated the permanent need for a specialized extraction provider to fulfill and secure the cannabis supply chain for medical and recreational consumers. With our significant first-mover advantage, deep expertise, leading-edge proprietary technology to manufacture and develop high-quality cannabis oil and concentrate products at commercial scale, we have quickly been able to execute several major contracts already and continue to see robust demand for our specialized products and services and are well positioned to achieve strong revenue growth as a dominant extraction company in the cannabis industry.”

As an agnostic supplier of pharmaceutical grade cannabis oil concentrates to the global cannabis industry, MediPharm Labs has demonstrated its ability to strengthen and further secure the domestic supply chain for high-demand cannabis oil. This new supply agreement, combined with a large, long-term oil supply agreement previously announced with Canopy Growth Corporation, represents less than 10 percent of MediPharm Labs’ annual extraction capacity of 150,000 kilograms, which is currently being expanded to 250,000 kilograms of annual extraction capacity, with completion expected in the second quarter of 2019.

To date, MediPharm Labs has completed four private-label wholesale agreements for cannabis oil concentrate supply (including Canopy Growth Corporation) and five long-term cannabis concentrate program (tolling) agreements with James E. Wagner Cultivation Corp., Emerald Health Therapeutics, Inc., INDIVA Limited, The Supreme Cannabis Company, Inc. and TerrAscend Corp.  Additionally, the company has completed bulk purchases and/or off-take agreements with 13 licensed producers securing dried cannabis supply to build MediPharm’s oil inventories for private-label sale. The company also continues to make progress on new partnership agreements with additional licensed producers and branded product manufacturers for cannabis private-label manufacturing, as well as partnerships to purchase cannabis concentrates for global export for private-label and research and development.

Founded in 2015, MediPharm Labs is a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence.

Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

Leave a Reply

Your email address will not be published. Required fields are marked *